Gyre Therapeutics, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances
Gyre Therapeutics, Inc. (GYRE) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances of $474.00 thousand for the 12-month period ending 2015-12-31, per its 10-K filed 2016-03-09.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues · last filed 2016-03-09
- Gyre Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for the quarter ending 2015-12-31 was $0.00.
- Gyre Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for fiscal 2015 was $474.00K, a 36.38% decline from fiscal 2014.
- Gyre Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for fiscal 2014 was $745.00K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 12 month |
|---|---|---|---|
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-09 | $474.00K 10-K · filed 2016-03-09 | |
| 2015-09-30 | $474.00K 10-Q · filed 2015-11-05 | ||
| 2014-12-31 | $745.00K 10-K · filed 2016-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |